Table 3.
Non HCT cellular therapies using manipulated cells in 2016
| Number of patients | DLI | MSC | NK cells | Selected/expanded T cells or CIK | Regulatory T cells (TREGS) | Genetically modified T cells | Dendritic cells | Expanded CD34+ cells | Genetically modified CD34+ cells | Other | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | ||
| GvHD | 421 | 2 | 4 | 31 | 1 | 11 | 36 | ||||||||||||
| Graft enhancement | 722 | 17 | 4 | 5 | 20 | 1 | 14 | 1 | 75 | 22 | |||||||||
| Autoimmune dis. | 9 | 19 | |||||||||||||||||
| Genetic disease | 1 | 1 | 1 | ||||||||||||||||
| Infection | 4 | 157 | 7 | ||||||||||||||||
| Malignancy | 1 | 9 | 32 | 3 | 28 | 6 | 29 | 3 | 45 | 1 | 8 | 16 | 1 | ||||||
| DLI for residual disease | 458 | ||||||||||||||||||
| DLI for relapse | 1329 | ||||||||||||||||||
| DLI per protocol | 370 | ||||||||||||||||||
| Regenerative medicine | 5 | 8 | 1 | 14 | 79 | ||||||||||||||
| Total | 2879 | 458 | 33 | 14 | 0 | 213 | 3 | 59 | 0 | 7 | 29 | 3 | 45 | 16 | 1 | 1 | 8 | 124 | 139 |
Numbers of cellular therapies in Europe 2016 by indication, donor type and cell source